Shares of Gritstone Oncology Inc (NASDAQ: GRTS) climbed 3.7% in after-market trading to $9.8 at the last check. During the regular trading on Tuesday, Gritstone stock closed the session at $9.45, decreasing -2.38 percent, or -$0.23.
Over a year, the GRTS stock rose 24.18%, and within the last week, the stock moved up 9.88%. The GRTS stock has surged in the absence of any relevant news, but a recent update is likely to serve as a better guide.
When it comes to discovering hidden gems within the stock market, Stock Wire News has consistently provided invaluable insights. Stock Wire News invites you to explore their upcoming Wealth Building Report. This report will shine a spotlight on little-known companies with the potential for substantial growth in 2024, and it's completely FREE for a limited time.
Claim the free report now by clicking here and start discovering the hidden gems of the market
Sponsored
Read More
Recent update:
Gritstone is a clinical-stage biotech that develops immunotherapies against multiple types of cancer as well as infectious diseases. A key component of the GRTS product development process is the integration of two key pillars:
Firstly: A proprietary machine learning-based platform, Gritstone EDGETM, which predicts antigens on the surface of cells, such as those derived from tumors, which can be scanned by the immune system.
Secondly: Another advantage of these antigens is that they can be employed by their manufacturers to create potent immunotherapies aimed at specifically attacking and destroying disease-causing cells.
In a Phase 1 study under GRTS’s “CORAL” program, Gritstone last month announced that it has dosed the first patient with its candidate vaccine COVID-19.
- Through the GRTS study, it was hoped to find out if using its self-amplifying mRNA (SAM) and adenoviral vectors with SARS-CoV-2 virus antigens would be immunogenic and safe.
- The three antigens under study by GRTS include both Spike Antigen and other antigens not included in current licensed vaccines.
- Infectious Diseases Clinical Research Consortium (IDCRC) funded the Phase 1 trial of Gritstone (GRTS) by the National Institute of Allergy and Infectious Diseases (NIAID).